A study of the efficacy and safety of albendazole (Zentel) in the treatment of intestinal helmenthiasis in Kenyan children less than 2 years of age
| dc.contributor.author | Estambale, Benson B. | |
| dc.contributor.author | Pamba, HO | |
| dc.contributor.author | Bwibo, NO. | |
| dc.contributor.author | Chunge, CN. | |
| dc.date.accessioned | 2018-06-12T08:42:39Z | |
| dc.date.available | 2018-06-12T08:42:39Z | |
| dc.date.issued | 1989-03 | |
| dc.identifier.issn | https://www.ncbi.nlm.nih.gov/pubmed/2591328 | |
| dc.identifier.uri | http://ir.jooust.ac.ke:8080/xmlui/handle/123456789/1269 | |
| dc.description.abstract | One hundred children comprising of 57 males and 43 females aged between 8 and 24 months entered the study. 46 children had single and 54 children had multiple helminth infections. All children received albendazole 200 mg (10 ml) suspension as a single dose. Albendazole proved very effective and safe in the treatment of single and multiple helminth infections in children under 2 years of age, achieving cure rates of 100% in both Ascaris lumbricoides and Necator americanus respectively, 83% in Trichuris trichiura and 66% in Hymenolepis nana. Treatment of polyparasitism appears to be of benefit in improving nutritional status using haemoglobin concentrations as an index. | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | PubMed | en_US |
| dc.title | A study of the efficacy and safety of albendazole (Zentel) in the treatment of intestinal helmenthiasis in Kenyan children less than 2 years of age | en_US |
